Rituximab

Phase 2UNKNOWN

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Steroid-Refractory Chronic GVHD

Conditions

Steroid-Refractory Chronic GVHD

Trial Timeline

May 1, 2007 → May 1, 2009

NCT ID

NCT00472225

About Rituximab

Rituximab is a phase 2 stage product being developed by Roche for Steroid-Refractory Chronic GVHD. The current trial status is unknown. This product is registered under clinical trial identifier NCT00472225. Target conditions include Steroid-Refractory Chronic GVHD.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02654379	Pre-clinical	Completed	Dec 18, 2015	Sep 29, 2017	Off-Label Use
NCT02626845	Approved	Terminated	Dec 1, 2015	Jul 1, 2017	Granulomatosis With Polyangiitis (Wegener's Granulomatosis)
NCT01987505	Phase 3	Completed	Nov 11, 2013	Apr 11, 2017	Lymphoma, Non Hodgkin
NCT01750697	Phase 2	Completed	May 23, 2013	May 10, 2018	Granulomatosis With Polyangiitis
NCT01684865	Pre-clinical	Completed	Oct 22, 2012	Nov 27, 2017	Non-Hodgkin's Lymphoma
NCT01609023	Pre-clinical	Completed	Apr 1, 2012	Nov 1, 2015	Lymphocytic Leukemia, Chronic
NCT01613027	Pre-clinical	Completed	Feb 1, 2012	Sep 1, 2015	Rheumatoid Arthritis
NCT01641952	Pre-clinical	Completed	Oct 1, 2011	Jan 1, 2015	Rheumatoid Arthritis
NCT01066598	Phase 2	Terminated	May 1, 2010	Aug 1, 2011	Graft Versus Host Disease
NCT01178086	Pre-clinical	Completed	Feb 22, 2010	Jun 30, 2015	Lymphocytic Leukemia, Chronic
NCT01071798	Pre-clinical	Completed	Jan 1, 2010	Oct 1, 2014	Rheumatoid Arthritis
NCT01118234	Phase 3	Completed	Dec 1, 2009	Jul 1, 2019	Chronic Lymphocytic Leukemia
NCT02536664	Pre-clinical	Completed	Sep 1, 2009	Jun 1, 2014	Follicular Lymphoma
NCT02461290	Pre-clinical	Completed	Apr 1, 2008	Nov 1, 2013	Follicular Lymphoma
NCT02622503	Pre-clinical	Completed	Apr 1, 2008	Aug 1, 2008	Rheumatoid Arthritis
NCT00509184	Phase 2	Completed	Mar 1, 2008	Apr 1, 2013	Lymphoma, Malignant
NCT00774462	Phase 2	Completed	Jan 1, 2008	Dec 1, 2011	Myositis
NCT00531089	Phase 2	UNKNOWN	Dec 1, 2007	Jan 1, 2011	Thrombotic Thrombocytopenic Purpura
NCT00963703	Pre-clinical	Completed	Dec 1, 2007	Mar 1, 2012	Rheumatoid Arthritis
NCT00645606	Phase 3	Completed	Dec 1, 2007	Jul 1, 2017	Leukemia

Competing Products

1 competing product in Steroid-Refractory Chronic GVHD

See all competitors

Product	Company	Stage	Hype Score
Ruxolitinib	Novartis	Approved	85

Other Products from Roche

EmicizumabApproved

rituximab + methotrexate + methylprednisolone + acetaminophen + antihistamineApproved

RituximabApproved

mycophenolate mofetil [CellCept]Approved

saquinavir/ritonavir + atazanavir/ritonavirApproved